{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:00:41Z","timestamp":1785477641593,"version":"3.56.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with limited therapeutic options for patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT). While CD123-targeted therapies and CAR T-cell infusion have shown promise, achieving durable remission without consolidative transplantation remains challenging. We report a pioneering \u201ctriple-integrated\u201d consolidation strategy in a 55-year-old male with relapsed\/refractory BPDCN and central nervous system involvement who lacked a suitable HLA-matched donor. After achieving a complete metabolic response with persistent bone marrow minimal residual disease (MRD) following Hyper-CVAD chemotherapy, the patient underwent high-dose conditioning and autologous stem cell transplantation (ASCT) sequentially followed by autologous CD123 CAR T-cell infusion (1.74\u00d710\n                    <jats:sup>6<\/jats:sup>\n                    \/kg). The clinical course was complicated by Grade 3 cytokine release syndrome and suspected immune effector cell-associated HLH-like syndrome (IEC-HS), which were successfully managed with glucocorticoid and emapalumab. Notably, ASCT served as a \u201chematopoietic rescue\u201d for CAR-T-induced prolonged cytopenia. To prevent late clonal escape, maintenance therapy with the BCL-2 inhibitor venetoclax was initiated post-transplant. The patient achieved sustained MRD-negative CR with a disease-free survival exceeding 13 months. This multimodal paradigm\u2014combining intensive cytoreduction, targeted immunotherapy with marrow rescue, and molecular maintenance\u2014provides a feasible and potentially curative alternative for BPDCN patients in the \u201cno-donor\u201d setting.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1922400","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:38:26Z","timestamp":1785476306000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature"],"prefix":"10.3389","volume":"17","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biping","family":"Deng","sequence":"additional","affiliation":[{"name":"Cytology Laboratory, Beijing Gobroad Boren Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma Research Center, Beijing GoBroad Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27737","article-title":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN): 2025 update on diagnosis, pathophysiology, risk assessment, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03922.x","article-title":"Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q","volume":"25","author":"Mitteldorf","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v122.21.2502.2502","article-title":"Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition","volume":"28","author":"Sapienza","year":"2014","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-133391","article-title":"Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant","volume":"4","author":"Yun","year":"2020","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006645","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00034","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14954","article-title":"Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study","volume":"179","author":"Kharfan-Dabaja","year":"2017","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.295","article-title":"Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis","volume":"18","author":"Kharfan-Dabaja","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01087-z","article-title":"Tagraxofusp: First global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.36401\/jipo-23-43","article-title":"Overcoming tagraxofusp-erzs monotherapy resistance in blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world clinical setting","volume":"7","author":"Dhakal","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/ijms24032718","article-title":"CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm","volume":"24","author":"Pelosi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/17474086.2021.1988848","article-title":"Targeting CD123 in BPDCN: an emerging field","volume":"14","author":"DiPippo","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/s41467-022-29669-8","article-title":"Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells","volume":"13","author":"Cai","year":"2022","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0777-1","article-title":"CD28\/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"Bole-Richard","year":"2020","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood.v130.suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6074.tumimm18-pr14","article-title":"Abstract PR14: CD123CAR displays clinical activity in relapsed\/refractory (r\/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): safety and efficacy results from a phase 1 study","volume":"8","author":"Budde","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-172975","article-title":"Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival","volume":"8","author":"Shimony","year":"2024","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7101","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Mart\u00edn-Mart\u00edn","year":"2016","journal-title":"Oncotarget"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011817","article-title":"Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001316","article-title":"Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm","volume":"43","author":"Sukswai","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqac174","article-title":"Expanding the immunophenotypic spectrum of neoplastic and reactive plasmacytoid dendritic cells","volume":"159","author":"Wu","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002474","article-title":"Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients","volume":"4","author":"Laribi","year":"2020","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.3390\/cancers15215149","article-title":"Immune effector cell-associated HLH-like syndrome: a review of the literature of an increasingly recognized entity","volume":"15","author":"Fugere","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-02083","article-title":"Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm","volume":"44","author":"Pemmaraju","year":"2026","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01358","article-title":"Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML","volume":"9","author":"Yao","year":"2019","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1182\/blood.V130.Suppl_1.1359.1359","article-title":"Treating relapsed \/ refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3390\/ijms25031454","article-title":"Breakthrough in blastic plasmacytoid dendritic cell neoplasm cancer therapy owing to precision targeting of CD123","volume":"25","author":"Zanotta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.3390\/ijms26062732","article-title":"Immunotherapies targeting CD123 and CD303: a new frontier in treating blastic plasmacytoid dendritic cell neoplasm","volume":"26","author":"Galati","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621268","article-title":"Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm","volume":"125","author":"Aoki","year":"2015","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s43152-024-00055-4","article-title":"The role of cancer-specific target antigens in CAR T cell therapy in hematological Malignancies","volume":"5","author":"Khan","year":"2024","journal-title":"Curr Tissue MicroenvironRep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s43152-024-00053-6","article-title":"Comprehensive review on the effect of stem cells in cancer progression","volume":"5","author":"Das","year":"2024","journal-title":"Curr Tissue MicroenvironRep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1998.16.8.2803","article-title":"Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution","volume":"16","author":"Fouillard","year":"1998","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","article-title":"Sequential CD19\/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma","volume":"11","author":"Wu","year":"2021","journal-title":"Blood Cancer J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2608209","article-title":"Current status and future potential of CD123-based targeted therapies for acute leukemia","volume":"25","author":"Arslan","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70157","article-title":"Managing treatment-emergent immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome following CAR-T cell therapy: a case-based review of the use of emapalumab","volume":"44","author":"Donzelli","year":"2026","journal-title":"Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc1808354","article-title":"Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm","volume":"379","author":"Agha","year":"2018","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26417","article-title":"Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm","volume":"97","author":"Gangat","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1922400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:38:27Z","timestamp":1785476307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1922400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2026.1922400"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1922400","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1922400"}}